Cogent Biosciences (COGT) vs Ionis Pharmaceuticals (IONS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cogent Biosciences (COGT) has outperformed Ionis Pharmaceuticals (IONS) over the past year, losing 27.3% versus a loss of 65.1%. Over five years, COGT leads with a +219.6% price change compared with -8.5% for IONS. Cogent Biosciences is the larger company by market cap ($4.65 billion vs $4.43 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | IONS |
|---|---|---|
| Share price | $26.72 | $26.58 |
| Market cap | $4.65B | $4.43B |
| 1-day change | -3.70% | -2.35% |
| YTD return | -24.79% | -66.40% |
| 1-year return | -27.33% | -65.07% |
| 5-year return | +219.56% | -8.50% |
| EPS (TTM) | $-2.26 | $-3.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $943.71M |
| Revenue growth (YoY) | — | +33.83% |
| Net income (latest FY) | $-328.94M | $-381.39M |
| Gross margin | — | 98.31% |
| Operating margin | — | -40.45% |
| Net margin | — | -40.41% |
| 52-week high | $43.73 | $86.74 |
| 52-week low | $26.36 | $26.53 |
| Distance from 52-week high | -38.91% | -69.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +108.95% | +155.19% |
| Average volume | 2.07M | 3.91M |
| Shares outstanding | 173.99M | 166.55M |
| Employees | 258 | 1,485 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- COGT has outperformed IONS by 37.7 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,485 employees
COGT vs IONS FAQ
Which is bigger, Cogent Biosciences or Ionis Pharmaceuticals?
Cogent Biosciences (COGT) is larger, with a market capitalization of $4.65B compared with $4.43B for Ionis Pharmaceuticals (IONS).
Which stock has performed better over the past year, COGT or IONS?
COGT returned -27.33% over the past 12 months, compared with -65.07% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Ionis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.